TrialCancer medicine2020

nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients.

Makoto Ueno et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.